HC Wainwright reiterated their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $17.00 price objective on the biopharmaceutical company’s stock.
Palatin Technologies Trading Down 0.9 %
Palatin Technologies stock opened at $1.09 on Thursday. The stock has a market cap of $21.31 million, a P/E ratio of -0.52 and a beta of 0.99. Palatin Technologies has a 52 week low of $0.68 and a 52 week high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last issued its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) EPS for the quarter. Research analysts anticipate that Palatin Technologies will post -2.03 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Palatin Technologies
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
See Also
- Five stocks we like better than Palatin Technologies
- Trading Halts Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What are earnings reports?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Bank Stocks – Best Bank Stocks to Invest In
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.